# Sangamo Therapeutics, Inc. (SGMO) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/SGMO
## Company Profile
- Ticker: SGMO
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Gene Therapy
## Stock Data
- Close: 0.074 USD
- Market cap: Not available USD
- Last updated: 2026-06-23
## Business Overview
### Genomic Medicine Company
Sangamo Therapeutics translates zinc finger epigenetic regulators, gene therapy, and delivery technologies into potential medicines for severe neurological and other serious diseases.
### Zinc Finger Technology Platform
Sangamo’s engineered zinc finger proteins can be configured for gene regulation, editing, and epigenetic control. The platform supports both internally developed medicines and partnered programs across neurological and systemic diseases.
### ST-920 in Fabry Disease
Isaralgagene civaparvovec, formerly ST-920, is Sangamo’s wholly owned gene therapy candidate for Fabry disease. The company is pursuing the FDA Accelerated Approval pathway through a rolling BLA submission and has submitted the preclinical and clinical modules while advancing the chemistry, manufacturing, and controls module.
### Neurology Pipeline
Sangamo’s neurology pipeline includes ST-503 for intractable chronic neuropathic pain caused by small fiber neuropathy. The company has also held constructive discussions with the U.K. MHRA regarding a potential study in prion disease.
### Internal and Partnered Development
Sangamo combines wholly owned programs such as its Fabry gene therapy with collaborations that apply zinc finger technology to partner-selected targets. This model provides external validation and funding while preserving direct ownership of selected high-value assets.
## Why The Stock Is Moving

The latest monitored company update is “Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milest….” The corresponding closing-price reaction is not yet available.

## Future Catalysts

- Completion of the CMC module for the rolling BLA submission of isaralgagene civaparvovec could occur as early as summer 2026, subject to Sangamo obtaining sufficient additional funding.
- The companion diagnostic antibody assay has been accepted by the FDA’s CDRH for PMA review, making future PMA and BLA interactions important regulatory milestones for the Fabry program.
- Six sites have been activated for the Phase 1/2 STAND study of ST-503, with enrollment and initial data expected to test the chronic neuropathic pain program.

## Recent News
- 2026-08-12 20:01 EST — [Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones](https://biopharmsignal.com/news/SGMO/sangamo-therapeutics-selects-successful-bidders-following-competitive-asset-auct-225ebf46) — Source: Sangamo Therapeutics, Inc.
- 2026-06-23 12:05 EST — [Sangamo Therapeutics Enters Into Asset Sale Agreements with Lilly and Astellas](https://biopharmsignal.com/news/SGMO/sangamo-therapeutics-enters-into-asset-sale-agreements-with-lilly-and-astellas-bbbd2927) — Source: Sangamo Therapeutics, Inc.
- 2026-06-08 12:05 EST — [Sangamo Therapeutics Announces Exploration of Strategic Alternatives to Maximize Value for Stakeholders](https://biopharmsignal.com/news/SGMO/sangamo-therapeutics-announces-exploration-of-strategic-alternatives-to-maximize-5109c181) — Source: Sangamo Therapeutics, Inc.
- 2026-05-14 20:01 EST — [Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results](https://biopharmsignal.com/news/SGMO/sangamo-therapeutics-reports-recent-business-highlights-and-first-quarter-2026-f-f0b80f3a) — Source: Sangamo Therapeutics, Inc.
- 2026-05-11 20:05 EST — [Sangamo Therapeutics Announces First Quarter 2026 Earnings Call](https://biopharmsignal.com/news/SGMO/sangamo-therapeutics-announces-first-quarter-2026-earnings-call-fce096a8) — Source: Sangamo Therapeutics, Inc.